Vanda gets EU orphan designation for imsidolimab in pustular psoriasis
Vanda Pharmaceuticals says the European Commission granted orphan designation for imsidolimab for the treatment of generalized pustular psoriasis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.